Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NV (STU:KH6) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
NewAmsterdam Pharma Co NV Net Margin % Related Terms
NewAmsterdam Pharma Co NV Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:KH6 vs ARQT, IDYA, ALMS: Net Margin % Comparison
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Net Margin % distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (STU:KH6) has a Net Margin % of -1,733.16% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #738 out of 944 companies in the Biotechnology industry, placing it in the top 78.2%.
Is NewAmsterdam Pharma Co NV's Net Margin % too high?
NewAmsterdam Pharma Co NV's current Net Margin % is -1,733.16%. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #738 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Net Margin % compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #738 out of 944 companies for Net Margin %. This places NewAmsterdam Pharma Co NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current Net Margin % is -1,733.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (STU:KH6) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.20, compared to a current price of €23.92 — trading 160% above its estimated fair value. The current Net Margin % is -1,733.16%. NewAmsterdam Pharma Co NV's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (STU:KH6), the current Net Margin % is -1,733.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (STU:KH6) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of €23.92 is trading 160% above its estimated GF Value™ of €9.20.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for STU:KH6:
Net Margin %: -1,733.16%
GF Value™: €9.20 vs. price of €23.92 (160% above fair value)
No single metric tells the full story. See the STU:KH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
38GF Score
Get the complete analysis for STU:KH6
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:KH6 has been successfully added to your 
